Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. - Wikidata - wikimedia - TriplyDB

Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.

Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.

http://www.wikidata.org/entity/Q33805859

about

Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis.Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid.A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice.Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.Autophagy and amino acid metabolism in the brain: implications for epilepsy.Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.

P2860

Q28533881-D44A2B69-7609-457F-BA26-AF6DE3329567 Q34379505-61033A82-69FA-43DC-A047-78E77B410FF2 Q34549521-6122CACC-B218-4116-B027-C9B81514DB32 Q37180223-D0D3E7BE-73BE-476D-94E5-CB5533508693 Q38242039-934676B6-4955-452E-82A8-C686A526119F Q38931988-099AA3CE-0C8A-4BDF-A210-D09A6C500F66 Q46921350-350F3EFA-3BEE-4CB4-9074-3C8A4D2D3B67 Q48501239-71F18C35-3620-47F6-A5F8-EF1A8DC49F80

P2860

Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.

http://www.wikidata.org/entity/Q33805859

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@ast

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@en

type

label

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@ast

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@en

prefLabel

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@ast

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@en

P1433

Q33805859-06DCADA8-8AB8-4B74-A372-C9829A975F5E

P1476

Q33805859-687C62E7-8637-4DFF-8613-6C7A0AF30831

P2093

Q33805859-77BE7E6C-FE05-4580-928B-8AE81074FFC6

Q33805859-785C0648-B3A5-4F1A-A852-3698297D9DE0

Q33805859-F3A4EDAA-0321-41D0-B768-6245DDE0F78E

P2860

Q33805859-0045A96C-EAEB-4C6C-9EF7-DA5E6CBF5BA7

Q33805859-0191394E-DEC8-44D7-9C7D-499400C59734

Q33805859-0897311A-DD25-408D-9363-C93C33A91B9B

Q33805859-0F4B86BF-5537-4B8B-8859-5483D0B715AE

Q33805859-1219102E-E38D-4075-956D-01851A3D349A

Q33805859-16549648-4E5F-41CD-913A-9FBB206B85EE

Q33805859-167B335B-6EFC-423B-9A53-A25CD9C4DA19

Q33805859-1711CF76-608F-4A33-ADC1-A77FC64A3466

Q33805859-224AFB7C-D587-4663-BD3A-4CC7380C6D6D

Q33805859-2779EC24-D440-45BA-BF49-5C5ADC539811

P304

Q33805859-C6B91653-CA54-457E-A1BB-7EDE4382A100

P31

Q33805859-81CB1494-3C47-4FE5-B34D-6EE2337683E1

P356

Q33805859-71A425DE-B3D6-49B8-8476-721EA343D62C

P433

Q33805859-A443692C-6D3D-4835-B8C4-2D308F825E41

P478

Q33805859-524AD319-C9B9-409E-9280-8DD7B29C5DEC

P577

Q33805859-F9E7F4F7-6813-48AF-BD72-1E85DD36733D

P5875

Q33805859-ED8AFA4A-8127-422F-8735-477DCECF44BF

P698

Q33805859-F94D3B22-E34A-4B12-8D1F-DEF0AC66B2E3

P932

Q33805859-62078597-1E4A-4494-9198-5FAC9DFA765F

P356

MCPHARMACOL.09.16

P1433

Molecular and cellular pharmacology

P1476

Developing Antiepileptogenic D ...... t of Rapamycin (mTOR) Pathway.

@en

P2093

Ling-Hui Zeng

http://www.w3.org/2001/XMLSchema#string

Michael Wong

http://www.w3.org/2001/XMLSchema#string

Nicholas R Rensing

http://www.w3.org/2001/XMLSchema#string

P2860

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

Growing roles for the mTOR pathway

The tuberous sclerosis complex

Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy

Immunoregulatory functions of mTOR inhibition.

P304

124-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4255/MCPHARMACOL.09.16

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43343388

http://www.w3.org/2001/XMLSchema#string

P698

20419051

http://www.w3.org/2001/XMLSchema#string

P932

2858431

http://www.w3.org/2001/XMLSchema#string